2. Signaling Pathways
  3. Apoptosis
  4. Ferroptosis

Ferroptosis

Ferroptosis

Ferroptosis

Related Products

PDF 0.68 MB

Ferroptosis is a non-apoptotic form of regulated cell death. It is distinct from other regulated cell death phenotypes, such as apoptosis and necroptosis. Ferroptosis is characterized by extensive lipid peroxidation, which can be suppressed by iron chelators or lipophilic antioxidants. Mechanistically, Ferroptosis inducers are divided into two classes: (1) inhibitors of cystine import via system xc− (e.g., Erastin), which subsequently causes depletion of glutathione (GSH), and (2) covalent inhibitors (e.g., (1S, 3R)-RSL3) of glutathione peroxidase 4 (GPX4). Since GPX4 reduces lipid hydroperoxides using GSH as a co-substrate, both compound classes ultimately result in loss of GPX4 activity, followed by elevated levels of lipid reactive oxygen species (ROS) and consequent cell death.

Ferroptosis is an iron- and ROS-dependent form of regulated cell death (RCD). Misregulated Ferroptosis has been implicated in multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-168030
    hCAIX-IN-23
    hCAIX-IN-23 (Compound 27) is a human carbonic anhydrase (hCA) inhibitor with Ki values of 10.4 and 8.5 nM for hCA IX and hCA XII, respectively. In addition to inhibiting hCA activity, hCAIX-IN-23 releases NO, exhibiting dual antitumor activity. hCAIX-IN-23 induces apoptosis by regulating mitochondrial caspase activity and the ferroptosis pathway (ferroptosis) through the downregulation of hCA IX and iron-regulatory protein expression. hCAIX-IN-23 is useful for renal cancer research.
    hCAIX-IN-23
  • HY-156066
    Ferrostatin-1 diyne
    		Inhibitor
    Ferrostatin-1 diyne (Fer-1 diyne) (compound 2) is a ferroptosis inhibitor that accumulates in lysosomes, mitochondria, and endoplasmic reticulum in cells, but its inhibition of ferroptosis is not dependent on the activity of lysosomes and mitochondria.
    Ferrostatin-1 diyne
  • HY-173613
    VEGFR-2-IN-68
    		Inducer
    VEGFR-2-IN-68 (13b) is a VEGFR-2 inhibitor, with an IC50 of 41.51 nM. VEGFR-2-IN-68 (13b) induces apoptosis and G2/M phase arrest. VEGFR-2-IN-68 (13b) exhibits anti-metastatic properties in cancer cells.
    VEGFR-2-IN-68
  • HY-168874
    TrxR1-IN-2
    		Inducer
    TrxR1-IN-2 (Compound 6a) is a TrxR1 inhibitor that covalently binds to the Cys475 and Sec498 sites of TrxR1, thereby inhibiting TrxR1 activity and leading to redox homeostasis disruption, which triggers apoptosis and ferroptosis.
    TrxR1-IN-2
  • HY-P10133
    PRDX3(103-112) SO3 modified, human
    PRDX3(103-112) SO3 modified, human is a marker of ferroptosis, and can be used for liver diseases study.
    PRDX3(103-112) SO3 modified, human
  • HY-176220
    GPX4-AUTAC
    		Inducer
    GPX4-AUTAC is a GPX4-targeting autophagy-mediated degrader (AUTAC). GPX4-AUTAC consists of an inhibitor ML162-yne (HY-153748), a degradation tag FBnG (HY-W073762) and a glycol linker (HY-W021401). GPX4-AUTAC promotes the ubiquitination of GPX4 by E3 ligase TRAF6, and enhances the binding with GPX4 and p62, leading to the selective autophagy-dependent degradation of GPX4. GPX4-AUTAC significantly induces ferroptosis and shows a potent anti-cancer activity in breast cancer cells, breast cancer-derived organoids (PDOs) and MDA-MB-231 tumor xenograft mice model, with potent synergistic effects when combined with Sulfasalazine (SAS) (HY-14655) or chemotherapy drugs (Paclitaxel (HY-B0015) or Cisplatin (HY-17394)).
    GPX4-AUTAC
  • HY-155158
    Anticancer agent 147
    		Inducer
    Anticancer agent 147 (compound 6j) is a derivative of sophoridine (HY-N1373) and is a ferroptosis inducer. Anticancer agent 147 can promote the accumulation of intracellular Fe2+, reactive oxygen species (ROS) and MDA, increase ER stress, and upregulate the expression of the activating transcription factor ATF3. Anticancer agent 147 has good anti-liver cancer effects in vitro and in vivo.
    Anticancer agent 147
  • HY-161332
    Antitumor agent-143
    		Inducer
    Antitumor agent-143 (compound 2c) is an antitumor agent that blocks cell proliferation of A549 cells during the S phase and induces an early apoptosis. Antitumor agent-143 induces cell death via ferroptosis, apoptosis by a ROS-mediated mitochondrial dysfunction pathway and GSDMD-mediated pyroptosis.
    Antitumor agent-143
  • HY-173313
    Ferroptosis-IN-19
    		Inhibitor
    Ferroptosis-IN-19 (compound C18) is a strong cellular ferroptosis inhibitor with an IC50 value of 0.097 μM. Ferroptosis-IN-19 shows high metabolic stability and favorable BBB permeability prediction. Ferroptosis-IN-19 has in vivo neuroprotection against ischemic brain injury in mice.
    Ferroptosis-IN-19
  • HY-163286
    BODIQPy-TPA
    		Inducer
    BODIQPy-TPA is a lipophilic probes, which induces ferroptosis in B16 and HepG2 cells upon light irradiation through lipid peroxidation. BODIQPy-TPA reveals a maximum absorption wavelength of 488 nm and a maximum emission wavelength above 640 nm.
    BODIQPy-TPA
  • HY-N0111S
    Coenzyme Q10-d6
    		Inhibitor
    Coenzyme Q10-d6 is deuterium labeled Coenzyme Q10. Coenzyme Q10 is an essential cofactor of the electron transport chain and a potent antioxidant agent.
    Coenzyme Q10-d<sub>6</sub>
  • HY-172225
    [Ru(phen)2(HMPIP)](PF6)2
    		Inducer
    [Ru(phen)2(HMPIP)](PF6)2 (Compound 6A) is an anti-tumor agent. [Ru(phen)2(HMPIP)](PF6)2 can inhibit the proliferation and migration of HepG2 liver cancer cells, and induce apoptosis, autophagy, cell cycle arrest and ferroptosis of HepG2 liver cancer cells. [Ru(phen)2(HMPIP)](PF6)2 exerts its anti-tumor activity by stimulating immune response to increase CD8+ T cells.
    [Ru(phen)2(HMPIP)](PF6)2
  • HY-B0450AG
    Ciclopirox olamine (GMP)
    		Inhibitor
    Ciclopirox (olamine) (GMP) is Ciclopirox olamine (HY-B0450A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Ciclopirox (HOE296b) is a synthetic antifungal agent that can be used for superficial mycoses reseaech. Ciclopirox olamine has a very broad spectrum of activity and inhibits dermatophytes, yeasts, molds, and many Gram-positive and Gram-negative species pathogenic.
    Ciclopirox olamine (GMP)
  • HY-10284S3
    Linagliptin-d3-1
    		Inhibitor
    Linagliptin-d3-1 (BI 1356-d3-1) is the deuterium labeled Linagliptin (HY-10284). Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.
    Linagliptin-d<sub>3</sub>-1
  • HY-B0450R
    Ciclopirox (Standard)
    		Inhibitor
    Ciclopirox (Standard) is the analytical standard of Ciclopirox. This product is intended for research and analytical applications. Ciclopirox (HOE296b) is a synthetic and orally active antifungal agent that can be used for superficial mycoses reseaech. Ciclopirox olamine has a very broad spectrum of activity and inhibits dermatophytes, yeasts, molds, and many Gram-positive and Gram-negative species pathogenic. Ciclopirox also has anticancer and anti-inflammatory effect.
    Ciclopirox (Standard)
  • HY-17379R
    Atorvastatin hemicalcium salt (Standard)
    		Activator
    Atorvastatin (hemicalcium salt) (Standard) is the analytical standard of Atorvastatin (hemicalcium salt). This product is intended for research and analytical applications. Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
    Atorvastatin hemicalcium salt (Standard)
  • HY-163506
    Ebselen derivative 1
    		Inhibitor
    Ebselen derivative 1 (Compound 19) is a glutathione peroxidase (GPx) mimic with oral activity. Ebselen derivative 1 demonstrates significant protective effects against cisplatin (HY-17394)-induced hair cell (HC) damage both in vitro and in vivo, effectively reducing oxidative stress, apoptosis, and ferroptosis in hair cells. Ebselen derivative 1 can be utilized in the research of cisplatin (HY-17394)-induced hearing loss .
    Ebselen derivative 1
  • HY-173408
    Nur77 agonist-1
    		Inducer
    Nur77 agonist-1 (Compound 8f) is an orally active Nur77 agonist. Nur77 agonist-1 induces ferroptosis by upregulating Nur77 protein expression, increasing reactive oxygen species (ROS) and lipid peroxidation levels, and decreasing GPX4 protein expression. Nur77 agonist-1 has binding affinity to the ligand binding domain (LBD) of Nur77 (KD: 13.80 μM). Nur77 agonist-1 exhibits significant antiproliferative activity against a variety of breast cancer cells (IC50: 2.15-3.26 μM) and has low toxicity to normal cells. Nur77 agonist-1 can be used in breast cancer research.
    Nur77 agonist-1
  • HY-164008
    DTUN
    DTUN is a lipophilic hyponitrite radical initiator and can initiates lipid peroxidation. DTUN is a tool for research of ferroptosis.
    DTUN
  • HY-139012
    RC574
    		Inhibitor
    RC574 is a novel probucol analog with the activity to protect mouse hippocampal cells and primary cortical neurons from glutamate-induced oxidative cell death (ferroptosis) and increase glutathione peroxidase (GPx) 1 levels and activity.
    RC574
Cat. No. Product Name / Synonyms Application Reactivity
All Rights Reserved.
Download Ferroptosis Signaling Pathway Map.